

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Campochiaro et al.

Appl. No.:

10/526,127

Conf. No.:

2577

Filed:

28 February 2005

Title:

OCULAR GENE THERAPY

Art Unit:

Unassigned

Examiner:

Unassigned

Docket No.:

116566-002

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 37 C.F.R. 1.97, and 37 C.F.R. 1.98, Applicants request that a citation and examination of the references cited below, and on the attached PTO-1449 form be made during the course of examination of the above-identified application for United States patent. The references below were cited in the Search Report in the corresponding PCT application. A copy of the Search Report is enclosed.

U.S. PATENT DOCUMENTS

Document No.

Date

Inventor

6,267,954

7/31/01

Abitbol et al.

FOREIGN PATENT DOCUMENTS

Document No.

<u>Date</u>

Country

WO 0193897

12/13/01

WIPO

WO 0230982

4/18/02

WIPO

OTHER DOCUMENTS

Mori, Keisuke et al., "Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin," *American Journal of Pathology*, Vol. 159, No. 1, July 2001, pp. 313-320.

Ohno-Matsui, Kyoko et al., "Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment," *American Journal of Pathology*, Vol. 160, No. 2, February 2002, pp. 711-719.

1

Ozaki, H. et al., "Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization," *American Journal of Pathology*, Vol. 156, No. 2, February 2000, pp. 697-707.

Takahashi, Kyoichi et al., "Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment," *FASEB Journal*, Vol. 17, No. 8, May 2003, pp. 896-898.

Applicants look forward to early and favorable consideration of this matter.

Respectfully submitted,

BELL, BOXD & LLOYD LLC

Dean H. Nakamura

Reg. No. 33,981 P.O. Box 1135

Chicago, Illinois 60690-1135

Phone: (202) 955-6851

Dated: 15 February 2006

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Atty Docket No.	Application No.
116566-002	10/526,127
Applicant	
Campochiaro et al	•
Filing Date	Group
28 February 2005	Unassigned

PTO Form 1449

		U.S. PA	TENT DOCUMENT	S	•	-
Examiner's Initials	Document Number	Publication Date	Inventor	Class	Subclass	Filing Date If Appropriate
	6,267,954	7/31/01	Abitbol et al.			
						·

FOREIGN PATENT DOCUMENTS							
Examiner's	Document	Publication	·			Translation	
Initials	Number	Date	Country	Class	Subclass	Yes	No
	WO 0193897	12/13/01	WIPO				
	WO 0230982	4/18/02	WIPO				
		,					
							В

Examiner's	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
Initials	
	Mori, Keisuke et al., "Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin," <i>American Journal of Pathology</i> , Vol. 159, No. 1, July 2001, pp. 313-320.
	Ohno-Matsui, Kyoko et al., "Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment," <i>American Journal of Pathology</i> , Vol. 160, No. 2, February 2002, pp. 711-719.
	Ozaki, H. et al., "Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization," <i>American Journal of Pathology</i> , Vol. 156, No. 2, February 2000, pp. 697-707.
	Takahashi, Kyoichi et al., "Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment," <i>FASEB Journal</i> , Vol. 17, No. 8, May 2003, pp. 896-898.

Examiner:	Date Considered:
*Examiner: Initial if citation considered, whether or not	citation is in conformance with MPEP Section 609;
Draw line through citation if not in conformance and no	t considered. Include copy of this form with next
communication to applicant.	·

89425/F/1 Page 1